Economic burden of hidradenitis suppurativa based on healthcare resource utilization: German claims data analysis
The majority of HS-related claims were attributable to medications, followed by inpatient treatment, underscoring the need for therapies that provide long-term effectiveness and tolerability.
Authors
- Sylke Schneider‐Burrus (ORCID: https://orcid.org/0000-0002-9740-6845)
- Romy Bley
- Falk G. Bechara (ORCID: https://orcid.org/0000-0003-0418-521X)
- Claudia Grellmann
- S. N. Melnik
- Sandeep Kiri
- Tanja Tran (ORCID: https://orcid.org/0009-0004-6818-8537)
- Kathrin Schlüter
Institutions
- Ingenieurgesellschaft Auto und Verkehr (Germany) (DE)
- University Hospitals of the Ruhr-University of Bochum (DE)
- Forschungsinstitut Havelhöhe (DE)
- St. Josef-Hospital (DE)
- Ev. Diakonissenkrankenhaus Leipzig (DE)
- UCB Pharma (Germany) (DE)
- UCB Pharma (Belgium) (BE)
Publication Details
- Journal
- JDDG Journal der Deutschen Dermatologischen Gesellschaft
- Published
- 2025-11-28
- DOI
- https://doi.org/10.1111/ddg.15901
- Primary Topic
- Hidradenitis Suppurativa and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00